

Making life easier

A woman with long dark hair tied back, wearing a blue tank top and purple shorts, is sitting in a wheelchair on a tennis court. She is smiling and looking up. She is holding a tennis racket with both hands, one with a white wristband. The background shows a tennis net and a building.

You can do what you want to
do. You build your life

Tabitha

Sustainable growth leadership

Goldman Sachs Access to Medicine, 24 February 2021

Nassera Ahmed, Senior Director Sustainability
Ellen Bjurgert, Vice President Investor Relations


Making life easier

Ostomy Care, Continence Care, Wound & Skin Care and Interventional Urology




Coloplast has four business areas all with global sales presence

Group revenue 2019/20 by segment



Group revenue 2019/20 by geography



Our new strategy will drive continued long-term value creation through revenue and earnings growth



1) Constant currencies, based on FX rate as of September 29, 2020



Making lives easier
in the most sustainable way

Together!

Brian

Our plastic position

As a manufacturer of medical products made of plastic, Coloplast has a responsibility.

We embrace that responsibility and have clear priorities:

- Product safety and clinical performance cannot be compromised
- Single use products are the easiest and safest option for our users
- Sustainability should be easy for our users
- We need to identify new materials and support the development of new technologies
- Partnerships across the industry are essential

Supporting sustainable development with a strong emphasis on improving our environmental performance and investing up to DKK 250m¹ over the next 5 years

Our mission

Making life easier for people with intimate healthcare needs

Our 2025 priority

Improving products and packaging



Our 2025 priority

Reducing emissions

3 GOOD HEALTH AND WELL-BEING



13 CLIMATE ACTION



Our on-going commitment

Responsible operations

5 GENDER EQUALITY



8 DECENT WORK AND ECONOMIC GROWTH



10 REDUCED INEQUALITIES




1) Approximate split: DKK 150m in OPEX and DKK 100m in CAPEX

Coloplast Group - Ostomy Care / Continence Care / Wound & Skin Care / Interventional Urology




Our 2025 priority: Improving products and packaging


We will work on improving products and packaging by addressing material use



80% Packaging consisting
of renewable materials*



90% Packaging will be made
recyclable



50% Production waste
recycled


We work towards phasing out unwanted substances and target to be set during 2021

*Renewable materials are defined as either recycled or bio-based

Coloplast Group - Ostomy Care / Continence Care / Wound & Skin Care / Interventional Urology

Our 2025 priority: Reducing emissions

We are committed to reducing emissions while being a growth company



2025 target – Scope 1+2

0 Emissions from production

100% Renewable energy (PPAs and phase out
natural gas use)

2025 target – Scope 3

5% Limit on goods transported by air

50% of company cars are electric

10% Reduction in air travels compared to 18/19 level

Target to reduce emissions among suppliers to be set
during 2021

*19/20 Scope 1 + 2 emissions: 11,100 tonnes, Scope 3 emissions: 159,700 tonnes

*Coloplast is committed to
ambitious science-based
climate action
for a 1.5°C future*



SCIENCE
BASED
TARGETS

DRIVING AMBITIOUS CORPORATE CLIMATE ACTION

**BUSINESS
AMBITION FOR
1.5°C**



**OUR ONLY
FUTURE**

Our ongoing commitment: Responsible Operations

We continue our strong commitment to responsible operations which is our core values




■ 2025

100% White-collars trained in
Code of Conduct




■ 2025

2.0 Loss-time
injury rate*



■ 2025

30% Female
representation at
VP+ levels



■ 2025

75% of teams (Director
and above) meet diverse
team targets criteria**

Our ongoing commitment: Responsible Operations

Our mission inherently strives for better outcomes as well as better access to healthcare

Raising standards of care

Our partnership programme, Access to Healthcare, seeks to improve conditions within ostomy, continence and wound care. Established in 2007, the programme has so far supported +60 projects.

Education



Coloplast has partnered with the University of Rochester to develop a synthetic male pelvis model as well as a parallel online curriculum to enable global education opportunities.

Awareness



Build patient and practitioner awareness of coated intermittent catheters in Brazil and create a documented 'gold standard' patient pathway.

+60 projects globally



Access/Funding



Coloplast has partnered with Key Opinion Leaders and Patient organisations to advocate for better access and treatment opportunities. Over the past 5 years, Coloplast has successfully seen increased access and funding for IC in Japan, South Korea and Australia. Most recently Japan has also introduced increased funding for bowel management products.

Enabling better outcomes



Product and service outcomes

Products and services reduce ostomy re-admissions in the US by 55%¹



Coloplast Care

- ~1.8m consumers in our database in 30+ countries
- 83% expressed feeling an improved quality of life through their participation²



Educating and training for clinicians

- +850 ostomy and continence care nurses from +20 countries are involved in our advisory boards
- +700 participants at Continence Days and Ostomy Days


(1) SirikanRojanasarot, The Impact of Early Involvement in a Postdischarge Support Program for Ostomy Surgery Patients on Preventable Healthcare Utilization, JWOON, 2017;00(0):1-7.

(2) Coloplast Market Study, 2013, data-on-file (PM-00728)

Our ongoing commitment: Responsible Operations

We have initiated a very ambitious Clinical Performance Program to tackle the biggest issues users face

Users are challenged by skin irritation and urinary tract infections



We have made progress on key technologies and run clinical trials



Our ongoing commitment: Sustainability Governance

We have strengthened our governance of Sustainability



Board of Directors

Consists of six shareholder-elected and three employee-elected members.

Remuneration and Nomination Committee

Consists of three members appointed among the Board of Directors.



Executive Leadership Team

Consists of CEO, CFO, Operations, Innovation, Growth, and People & Culture

Audit Committee

Consists of four members appointed among the Board of Directors.



Sustainability unit

~10 FTEs dedicated to Sustainability with the responsibility of embedding sustainability in the organization and identifying new improvement areas. Anchored in Global Quality and Regulatory Affairs.

Q&A



Our mission

Making life easier for people
with intimate healthcare needs

Our values

Closeness... to better understand

Passion... to make a difference

Respect and responsibility... to guide us

Our vision

Setting the global standard
for listening and responding